Multinucleated tumor cells in clear cell renal cell carcinoma

Author:

Pacheco Richard R1ORCID,Binboga Kurt Busem2,Kosemehmetoglu Kemal3,Rothrock Aimi T1,Lightle Andrea1,Akgul Mahmut1ORCID

Affiliation:

1. Department of Pathology and Laboratory Medicine, Albany Medical Center , Albany, NY , US

2. Dana Farber Cancer Institute , Boston, MA , US

3. Department of Pathology, Hacettepe University , Ankara, Turkiye

Abstract

Abstract Objectives Multinucleated tumor cells (MTCs) in clear cell renal cell carcinoma (ccRCC) are not well understood. Methods Our study included ccRCC cases in a single institution between 2010 and 2019. We classified MTC as MTC with degenerative atypia (MTCD), MTC with no anaplasia (MTCNA), and MTC with anaplasia (MTCA). Clinicopathologic characteristics and outcomes were compared between MTC groups. Results In all, 92 of 256 people (36%) with ccRCC had MTC. People with ccRCC with MTCD and those with ccRCC but no MTC had similar clinicopathologic characteristics and outcomes. Also, MTCNA and MTCA were associated with larger tumor size, advanced pathologic tumor stage, higher World Health Organization/International Society of Urologic Pathologists nuclear grade, and higher metastatic potential (P < .001 for each parameter). Overall, MTCA was associated with an increased rate of recurrence (P = .004), higher metastatic potential (P < .001), and shorter time to metastasis (P = .033), regardless of tumor stage. Univariate Cox regression revealed MTCNA as a significant predictor of metastasis at 5 years (hazard ratio [HR], 4.171; 95% CI, 1.934-8.998); moreover, MTCA was a significant predictor of recurrence (HR, 5.723; 95% CI, 2.495-13.124), metastasis (HR, 12.024; 5.966-24.232), and death (HR, 5.661; 95% CI, 2.688-11.924) at 5 years. Conclusions Although MTCD may not be relevant in tumor grading, MTCNA and MTCA are associated with adverse outcomes.

Publisher

Oxford University Press (OUP)

Subject

General Medicine

Reference16 articles.

1. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours;Moch,2022

2. Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading;Dagher,2017

3. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters;Delahunt,2013

4. Frequency, incidence and survival outcomes of clear cell renal cell carcinoma in the United States from 1973 to 2014: a SEER-based analysis;Feng,2019

5. Renal cell carcinoma with syncytial giant cell component;Lloreta,2002

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3